
Collection of Selected Free Papers from the 9th International Conference on Alzheimer’s and Parkinson’s Disease AD/PD

Prague, Czech Republic, March 11-15, 2009

Editors
Abraham Fisher
Israel Hanin
Foreword

This is the fourth book of what is becoming a series of companion pieces to the bi-annual conferences on Alzheimer’s and Parkinson’s diseases (AD/PD). This book contains 56 papers written by selected authors, who had presented their research at the Ninth International Conference on Alzheimer’s and Parkinson’s Diseases: Advances, Concepts & New Challenges (AD/PD 2009), that took place on March 11-15, 2009 in captivating Prague, in the Czech Republic. The official proceedings (OP) of the Conference will be published early in 2010 by Karger, as a special issue of the journal Neurodegenerative Diseases.

The Prague meeting included over 2,300 scientific participants, and was the venue for several hundred invited talks, general talks, posters, and symposia. It was impossible to include all of the important scientific information presented at the meeting under one cover while, at the same time, meeting publishers’ cost and profit considerations. We, the co-organizers, therefore decided to restrict contributions to be published in the OP, to chapters based on ORAL, INVITED presentations at the meeting.

We also agreed that Medimond International Proceedings (Medimond) would publish a complementary book to the OP, based on FREE PAPERS presented at the Congress. This additional publication, to be issued in printed volume and CD Rom format, would expand the scope of available scientific information from the AD/PD 2009 proceedings.

Medimond’s policy is to provide rapid publication of conference proceedings. We, therefore, agreed with this publisher’s request that we, the editors, would only correct major mistakes or errors in scientific logic and fact. We would not concern ourselves with stylistic differences in expression by authors whose first language is other than English, nor with differences in font type, style, or referencing in these chapters. We have also not been too particular in the choice of chapters included in the book, in order to encourage diversity in the topics presented. Each author is solely responsible for the information provided in his/her chapter. The manuscripts have, nevertheless, received our general overview, with minor editorial changes inserted where necessary, in the interest of maintaining scientific integrity, while at the same time enabling the rapid publication of these findings. We trust that this book (and the accompanying CD), together with the OP, will provide the reader with a broader overview of the scope and richness of the program of the AD/PD 2009 conference.

Thus, in summary, we have agreed to allow Medimond to approach participants in the ADPD conference whom we, as co-organizers, were unable to invite to contribute a paper because of limitations in the size of the OP of the conference. In this manner, other scientists would at least have the opportunity to publish their work in this Medimond publication which, while a private product (hence each contributor to this volume was required to pay a fee for publication), will be associated in name with the ADPD meeting.
The papers have been scrutinized by us for quality before we approved this publication. Moreover, we would like to emphasize, as a disclaimer, that neither the ADPD meeting co-organizers, nor Kenes received any compensation whatsoever from Medimond for this product. This book is entirely a profit generator for Medimond, with the stipulation that we, the co-organizers, must give the product our stamp of approval before it can be published.

A thorough and extensive, peer-reviewed editorial process will be employed in the case of the OP document, which is presently in preparation.

Abraham Fisher, Ph.D.        Israel Hanin, Ph.D.
Index

Anosognosia in Alzheimer disease
Cho Hyun, M.D., Kwon Jee-Hyun, M.D., Kim Seon-Young, M.D. ................................. 1

P300 response in early DLB and AD patients shows different topographic distribution.
Bonanni L., Iorio E., Onofrj M., Tiraboschi P., Anzellotti F., Franciotti R., Manzoli L.,
Borreli I., Thomas A. ........................................................................................................... 9

Visual Art Improves Communication and Behaviour of AD Patients
Musella O., Carloni A., De Marino L., Di Bartolo E., Gaeta G., Di Maggio P.
and Fasanaro AM ................................................................................................................ 15

Prenatal Diesel Exhaust Exposure Causes Neurodegenerative Diseases in Adults
Sugamata M., Ihara T., Takeda K. ....................................................................................... 21

Theory of mind and executive abilities in individuals with Parkinson’s disease
Costa A., Oliveri M., Torriero S., Peppe A., Martini M., Coletta K., Carlesimo G. A.,
Caltagirone C. ..................................................................................................................... 25

An update on EHT 0202 preclinical and clinical development for Alzheimer’s Disease therapy
Desire L. .............................................................................................................................. 29

Polymorphisms of chemokine and chemokine receptor genes in Alzheimer’s and Parkinson’s Patients
Reale M., Gatta V., Di Nicola M., Stuppa L., Palka G., Iarlori C., Thomas A., Onofrj M.,
Gambi D. .................................................................................................................................. 33

Management of severe psychotic symptoms associated with Parkinson disease that needed a treatment in the psychiatric ward.
Joki Hideto, MD; Endo Masanao, MD; Tachiyama Tetsuya, MD; Kimura Katsuo, MD;
Nomiyama Tamaki, MD; Shimamura Megumi, MD; Yamada Hitoshi, MD; Takahashi Tatsuya, MD;
and Kuroiwa Yoshiyuki, MD ................................................................................................. 39

Maremmani C., Marini P., Ramat S., Purcaro C., Napolitano A., Vanni P., Serra P., Morano P.,
Palumbo V., Orsini M., Marconi R., Rossi G., Meco G. .......................................................... 41
Immune studies in peripheral blood of patients with alzheimer’s disease
Lombardi V.R.M., Etcheverría I., Fernández-Novoa L., Seoane S., Cacabelos R.  

CYP2D6, CYP2C19, CYP2C9 and CYP3A5 polymorphism in the Spanish population

Gender aspects in Mild cognitive Impairment (MCI) to Alzheimer’s Disease (AD) conversion. A Romanian epidemiological study.
Spiru L., Ioancio I., Nuta C., Turcu I.  

Aging, Neurodegenerative Disease and β-Secretase

Polygenic risk factors related to neurodegeneration in Alzheimer disease: calculation of a genetic predisposition score (gps)
Fernández-Novoa L., Llovo R., Tudoli I., Seoane S. and Cacabelos R.  

Multiple system atrophy and Alzheimer’s disease in association: coincidence or comorbidity?
Rusina R., Matěj R.  

A pilot, comparative epigenomic and metabolomic study in healthy elderly, adult and young people
Cucu N., Anton G., Radu LG, Turcu I., Spiru L.  

The PARS Study: Evaluating pre-motor Parkinson disease
Jennings Danna, Siderowf Andrew, Stern Matthew, Marek Kenneth and the PARS Investigators  

Logistic regression as a useful tool to explain genetic risk of stroke
Carril JC., Llovo R., Fernández-Novoa L., Cacabelos R.  

The effect of combination therapy of dopamine agonists for Parkinson’s disease
Nakamura Shinichiro, Kitami Makiko, Furukawa Yoshiyuki  

ACE-R: cross-sectional and longitudinal use for cognitive assessment
Larner AJ.  

Evidence for lipid alterations in lipid rafts from alzheimer’s disease human brain

The effect of glycosaminoglycans (gags) on amyloid formation and aggregate toxicity
Vilasi S., Irace G., Sirangelo I.  

Effects of donepezil in patients with various type of dementia
Asano S., Toyoda T., Yonekura I., Shimada S., and Tanishima T.
Arguments for the reconsideration of procaine as a potent therapeutic molecule in AD/PD
Turcu I., Spiru L. .................................................................................................................. 127

Marine natural products as αβ modulators
García-Palomero E., Usán P., García P., Delgado E., de Austria C., Sáiz G., Pérez M.A.,
Sánchez-Quésada J., Dorronsoro I., Castro A. and Medina M. ............................................ 135

Mixture of ferulic acid and garden angelica extract improves cognitive function in Alzheimer patients
Nakamura S., Sasaki K., Azekawa T., Itami A., Ito T., Kiyohara T., Kono K., Matsuda S.,
Mizuno Y., Miyahara S., Origasa H., Endo H., Yanagimachi A., Lee HS .............................. 141

Xanomeline binding to and activation of muscarinic receptors.
Jakubík J., Machová E., El-Fakahany E.E., and Doležal V. ............................................. 145

TGF-β1-induced TIAF1 self-association leads to apoptosis
Lee M.H., Lin S.R., Chang N.S. ........................................................................................... 149

Protofibrillar amyloid-beta down-regulates brain-derived neuro-trophic factor transcript iv in Alzheimer’s disease
Fahnestock M., Peng S., Marchese M., Garzon D., and Mufson E.J. ............................ 157

Endothelial damage and platelet activation in Alzheimer’s disease patients
Piazza F., Galimberti G., Conti E., Guerrato I., Isella V., Speranza T., Borroni B., Pogliani E.M.,
Padovani A. and Ferrarese C. ............................................................................................ 163

Cholesterol modulates amyloid beta peptide 1-42 channel formation in planar lipid membranes
Meleleo D., Notarachille G., Gallucci E. and Micelli S. ..................................................... 167

Effect of calcium and cadmium ions on amyloid beta peptide 1-42 channel activity
Notarachille G., Meleleo D., Gallucci E., Micelli S. ............................................................. 173

Role of nitric oxide in the αβ_{25-35} toxicity in vivo
Limón I.D., Díaz A., Mendieta L., Guzmán A., Martínez I., Espinosa B., Zenteno E.
and Guevara J. .................................................................................................................... 179

Presenilin 1 mediates cell-cell adhesion in transfected L-fibroblasts
Schwarzman A., Sarantseva S., Soloviev K., Talalaeva E., and Vitek M.P .................................. 187

Sirtuins as a link between ageing and neurodegeneration
Marques Oldriska, Oliveira Rita M., Moita Luis Ferreira, and Outeiro Tiago Fleming ........ 191

Neuronal Abnormality Topography and Discrimination of MCI developing AD
Musha T. and Matsuzaki H. ................................................................................................. 199

GDNF and IGF-1-induced Astrocytic Metallothionein-1 (MT-1) and -2 (MT-2) Protect Neurotoxicity (1)IGF-1
Watanabe Toshiaki ................................................................................................................. 205
<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>The homozygous weaver mouse as an animal model of parkinson’s disease</td>
<td>Martí J., Santa-Cruz MC., Serra R., Molina V. and Hervás JP.</td>
<td>213</td>
</tr>
<tr>
<td>Deletion of the gene encoding for the enzyme Methionine sulphoxide reductase A increases the toxicity of Aβ (1-42) in an in vivo model.</td>
<td>Minniti A., Inestrosa N. and Aldunate R.</td>
<td>217</td>
</tr>
<tr>
<td>Effects of copper on Aβ-induced pathological features in Caenorhabditis elegans.</td>
<td>Minniti A., Rebolledo D., Inestrosa N.</td>
<td>221</td>
</tr>
<tr>
<td>Anti-β-amyloid (Aβ) IgG levels in plasma of healthy people measured with a reliable immunoassay</td>
<td>Weber A., Minibeck E., Engelmaier A., Ehrlich H. J., Schwarz H. P.</td>
<td>225</td>
</tr>
<tr>
<td>Neuromodulatory actions of beta-amyloid on the DA release</td>
<td>Mura E., Preda S., Govoni S., Frattini P., Grilli M., Marchi M.</td>
<td>229</td>
</tr>
<tr>
<td>Overexpression of human amyloid precursor protein causes neurodegeneration and loss of synaptic proteins in transgenic Drosophila</td>
<td>Sarantseva S., Bolshakova O., Timoshenko Š., Vitek M., and Schwarzman A.</td>
<td>245</td>
</tr>
<tr>
<td>The Avian Ciliary Ganglion: A useful model for study of the effects of beta amyloid on neurotransmitter release</td>
<td>Mazalan Susan, Hart Elizabeth, &amp; Gray D. Bruce</td>
<td>249</td>
</tr>
<tr>
<td>Monitoring of Aβ fibrillization using an improved fluorimetric method.</td>
<td>Karafin A., Palumaa P. and Tõugu V.</td>
<td>255</td>
</tr>
<tr>
<td>Alzheimer’s β-amyloid deposits induce the c-Abl/p73 signaling in AD models.</td>
<td>Cancino G.I., Alvarez A.R.</td>
<td>261</td>
</tr>
<tr>
<td>Modified embryo organ culture model system for preclinical studies of growth factors-induced neural tissue differentiation in mammals</td>
<td>Stipić J. and Crnek-Kunstelj V.</td>
<td>267</td>
</tr>
<tr>
<td>The changes in the lipid phase of brain cell membranes in mice bearing experimental Alzheimer’s-like disease induced with the help of olfactory bulbectomy.</td>
<td>Burlakova E., Molochkina E., Gerasimov N., Goncharova I., Fatkullina L., Goloschapov A.</td>
<td>273</td>
</tr>
<tr>
<td>Effect of Proteasome Inhibition on MPP⁺-induced GSTP1 Expression in SH-SY5Y Cells</td>
<td>Neves Carvalho A., Marques C., Rodrigues E., Pereira P., Gama M. J.</td>
<td>279</td>
</tr>
</tbody>
</table>
Doxycycline, a 2nd generation tetracycline, protects neuronal cells against glutamate- but not against 6-OHDA-induced cytotoxicity

Developmental changes in calcium channels and D1-like receptors involved in the glutamatergic transmission onto rat basal forebrain cholinergic neurons
Momiyama T. ...................................................................................................................... 299

Aβ causes memory impairment by disturbing the jak2/stat3 axis in hippocampal neurons.
Chiba T., Yamada M., and Aiso S. ........................................................................................ 307

Dual Roles Of Amyloid-Beta And Secreted Forms Of Amyloid Precursor Protein In Culture

Link between Gangliosides, Sphingolipids and Alzheimer’s Disease
Grimm M.O.W., Grösgen S. and Hartmann T. ....................................................................... 317

Author Index ................................................................................................................... 321